Stammdaten
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Unternehmen & Branche
| Name | Biofrontera Inc. |
|---|---|
| Ticker | BFRI |
| CIK | 0001858685 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - Specialty & Generic |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 12,7 Mio. USD |
| Beta | 0,64 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 41,705,000 | -10,536,000 | -1.04 | 28,564,000 | 10,480,000 |
| 2025-09-30 | 10-Q | 6,988,000 | -6,649,000 | -0.62 | 15,415,000 | -2,581,000 |
| 2025-06-30 | 10-Q | 9,030,000 | -5,324,000 | -0.57 | 20,142,000 | -4,668,000 |
| 2025-03-31 | 10-Q | 8,588,000 | -4,203,000 | -0.47 | 16,588,000 | 500,000 |
| 2024-12-31 | 10-K | 37,321,000 | -17,759,000 | -3.22 | 22,101,000 | 4,433,000 |
| 2024-09-30 | 10-Q | 9,012,000 | -5,669,000 | -0.98 | 18,516,000 | 5,530,000 |
| 2024-06-30 | 10-Q | 7,839,000 | -257,000 | -0.05 | 21,574,000 | 10,911,000 |
| 2024-03-31 | 10-Q | 7,912,000 | -10,437,000 | -2.88 | 24,575,000 | -5,416,000 |
| 2023-12-31 | 10-K | 34,071,000 | -20,131,000 | -13.02 | 27,932,000 | 4,793,000 |
| 2023-09-30 | 10-Q | 8,896,000 | -6,342,000 | -4.64 | 34,104,000 | 1,038,000 |
| 2023-06-30 | 10-Q | 5,848,000 | -9,837,000 | -7.23 | 36,905,000 | 7,173,000 |
| 2023-03-31 | 10-Q | 8,733,000 | -7,478,000 | -5.60 | 41,965,000 | 16,751,000 |
| 2022-12-31 | 10-K | 28,674,000 | -640,000 | -0.61 | 50,884,000 | 23,878,000 |
| 2022-09-30 | 10-Q | 4,322,000 | -2,566,000 | -2.26 | 55,059,000 | 22,595,000 |
| 2022-06-30 | 10-Q | 4,457,000 | -850,000 | -0.90 | 53,626,000 | 17,233,000 |
| 2022-03-31 | 10-Q | 9,751,000 | 5,561,000 | 0.32 | 49,202,000 | 17,416,000 |
| 2021-12-31 | 10-K | 24,100,000 | -37,713,000 | 53,219,000 | 11,338,000 | |
| 2021-09-30 | 10-Q | 4,334,000 | -16,012,000 | -2.00 | 15,354,000 | -17,380,000 |
| 2021-06-30 | 10-Q | 5,855,000 | -3,661,000 | -0.46 | -1,368,000 | |
| 2021-03-31 | 10-Q | 4,744,000 | -3,534,000 | -0.44 | 2,294,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.